Representative Transactions*

• Pharmakon on IP diligence regarding a definitive senior secured loan agreement for up to $275 million (in two parallel $137.5 million investments) for Reata Pharmaceuticals
• Pharmakon on IP diligence in its non-dilutive term loan financing for up to $175M for ImmunoGen
• Royalty Pharma on IP diligence in its acquisition of an interest in Ionis' royalty in Biogen's SPINRAZA® (nusinersen) and Novartis' pelacarsen for up to $1.125B
• Pharmakon on IP diligence in its $100M loan agreement with Immunocore
• Royalty Pharma on IP diligence in its acquisition of a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals totaling up to $410M
• New Enterprise Associates on IP diligence related to Inversago Pharma’s $70M (USD) Series C financing
• Pharmakon on IP diligence in its $350M strategic financing for Insmed
• Royalty Pharma on IP diligence in its $425M funding agreements with Merck to co-fund the development of MK-8189
• Marshall Wace on IP diligence of Elektrofi's $40M Series B financing
• Royalty Pharma in its $450M investment in Cytokinetics Inc. based on the drug products aficamten and omecamtive mecarbil
• Royalty Pharma on IP diligence in its $2.025B strategic funding partnership as part of MorphoSys' $1.7B acquisition of Constellation Pharmaceuticals
• Royalty Pharma in its $342M acquisition of the royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK)
• Royalty Pharma in IP diligence for its $155M acquisition of royalty interest in the drug product seltorexant from Minerva Neuroscience
• Royalty Pharma in its $575M acquisition of the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis treatments owned by the Cystic Fibrosis Foundation
• Royalty Pharma in its $650M royalty purchase agreement with PTC Therapeutics, Inc. to acquire a portion of PTC’s royalty interest in Risdiplam
• Royalty Pharma in its $255M acquisition from Agios Pharmaceuticals, Inc., of sales-based royalty rights on worldwide net sales of Bristol Myers Squibb’s IDHIFA® (enasidenib)
• Royalty Pharma in its $220M acquisition of AiCuris Anti-infective Cures GmbH’s partial royalty interest in Prevymis™ (letermovir)
• Royalty Pharma in its $94M acquisition of Massachusetts General Hospital’s royalty interest in Entyvio (vedolizumab)
• Royalty Pharma in its $330M acquisition of Eisai Co., Ltd.’s royalties on sales of Epizyme Inc.’s soon-to-be-FDA-approved drug tazemetostat
• Royalty Pharma in its $100M equity investment (with options to invest up to an additional $100M) in Epizyme Inc.
• Royalty Pharma in its $827M acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta

* Includes experience from a prior firm

Speaking Engagements

• “Original Sin: How Origination Credit Is a Barrier to Diversity Goals,” Office for Diversity & Inclusion of the New York City Bar Association, October 2020 (Speaker)
• "Keys to Maximizing U.S. Patent Term,” China Pharma IP Summit 2019, October 2019 (Speaker)
• “Counteracting the flux of patent eligibility,” Managing Intellectual Property U.S. Patent Forum 2019, April 2019 (Speaker, panel)
• “Identifying Patent Examiner Biases and Making Them Work Using Legal Analytics,” Legal Analytics and the Business of Law Summit, November 2014 (Speaker, panel)